Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Abstract

The Task Force developed 67 evidence-based recommendations to assist clinicians in the care of patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal medical practice.

Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules

“…There is a considerable body of evidence that the measurement of serum CT concentrations in patients with thyroid nodules can lead to an earlier diagnosis of MTC than the exclusive use of imaging procedures and/or fine‐needle aspiration cytology (FNAC) 4, 5, 6, 7. However, there is some controversy regarding the screening of thyroid nodules with CT measurements as to whether this is a cost‐effective exercise in terms of reducing deaths 8, 9. In addition, different analytical, physiological, pharmacological and pathological factors may significantly reduce the specificity and overall accuracy of serum CT measurement 3.…”

“…Besides, the more recent AACE, AME and ETA's common document declared that routine measurement of basal CT may be useful and strongly recommended its measurement in certain high‐risk groups 14. Finally, the ATA's guidelines panel decided to not recommend either for or against routine measurement of serum CT in patients with thyroid nodules8 but recommend that physicians decide whether the technique is useful in the management of patients in their clinic 9. If CT screening is adopted it should be noted that depending on the assay used, 56%‐88% of subjects without thyroid disease usually show a CT level below the functional sensitivity, while 3%‐10% have CT levels >10 pg/mL 15, 16.…”

Personalized diagnostics of chromaffin tumors (pheochromocytoma, paraganglioma) in oncoendocrinology

“…Многие авторы считают, что это вариант син-дрома МЭН-2 без прижизненной манифе-стации других эндокринных неоплазий синд-рома МЭН-2. Подозрения в семейной форме МРЩЖ -наличие по крайней мере одного кровного родственника с МРЩЖ и отсут-ствие других проявлений синдрома МЭН-2 [32] (табл. 4)…”

“…Синдром MЭН-2A -наиболее частый синдром (55% всех син-дромов МЭН-2), как правило, встречается комбинация МРЩЖ и ФХ и/или опухоли па-ращитовидных желез у одного пациента либо у нескольких членов семьи. МРЩЖ -обычно первое проявление синдрома в воз-расте от 5 до 30 лет [32]. Частота МРЩЖ среди МЭН-2А -более 95%, ФХ -40-50%, множественных опухолей паращитовидных желез -10-20% [34].…”

Pathological and clinical findings in a series of 22 cases of medullary carcinoma of the thyroidat the korle-bu teaching hospital (1994-2013)

“…The relative proportion of MTC among thyroid malignancies varies across Africa [8][9][10][11] and globally [12][13][14]. For instance Sippel et al, in their study found that MTC accounts for approximately 10.0% of all thyroid malignancies [12], while Well et al, found 1-2% [14].…”